Medus Pharma宣布开展SKNJCT-004第二阶段临床研究，以非侵入性治疗皮肤BCC，开始在阿布扎比克利夫兰诊所招募患者

Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that the SKNJCT-004 phase 2 clinical study, to non-invasively treat BCC of the skin, has commenced patient recruitment in Cleveland clinic Abu Dhabi (CCAD). Earlier this year, in May 2025, SKNJCT-004 received "study may proceed" approval from the UAE Department of Health.

The study is expected to randomize thirty-six (36) patients in four sites in UAE. In addition to Cleveland Clinic Abu Dhabi (CCAD), the study is also expected to commence patient recruitment in Sheikh Shakbout Medical City (SSMC), Burjeel Medical City (BMC), Rashid Hospital (RH), Clemenceau Medical Center (CMC) and American Hospital of Dubai (AHD).

Insights Research Organization and Solutions (IROS), a UAE-based contract research organization, is coordinating the clinical study for the Company. IROS is a M42 portfolio company.